Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-24-043698
Filing Date
2024-10-18
Accepted
2024-10-18 16:11:03
Documents
4
Period of Report
2024-11-14

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20036093x2_def14a.htm DEF 14A 149139
2 GRAPHIC logo_oruka.jpg GRAPHIC 37750
3 GRAPHIC ny20036093x2_pc01.jpg GRAPHIC 549872
4 GRAPHIC ny20036093x2_pc02.jpg GRAPHIC 568514
  Complete submission text file 0001140361-24-043698.txt   1742014
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-22873 | Film No.: 241380856
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)